143 related articles for article (PubMed ID: 10084570)
1. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma.
Koong SS; Reynolds JC; Movius EG; Keenan AM; Ain KB; Lakshmanan MC; Robbins J
J Clin Endocrinol Metab; 1999 Mar; 84(3):912-6. PubMed ID: 10084570
[TBL] [Abstract][Full Text] [Related]
2. Use of lithium as an adjunct to radioiodine therapy of thyroid carcinoma.
Gershengorn MC; Izumi M; Robbins J
J Clin Endocrinol Metab; 1976 Jan; 42(1):105-11. PubMed ID: 1249178
[TBL] [Abstract][Full Text] [Related]
3. [Lithium as an adjuvant in the radioiodine therapy of thyroid cancer].
Schraube P; Kimmig B; zum Winkel K
Nuklearmedizin; 1984 Jun; 23(3):151-4. PubMed ID: 6435095
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
[TBL] [Abstract][Full Text] [Related]
5. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
[TBL] [Abstract][Full Text] [Related]
6. Iodine-131 treatment of thyroid cancer: relation between effective half-life and efficacy of treatment.
Matsushita T; Toyota S; Katoh N; Nakagawa T
Radiat Med; 1994; 12(4):167-70. PubMed ID: 7809410
[TBL] [Abstract][Full Text] [Related]
7. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
8. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study.
Pacini F; Ladenson PW; Schlumberger M; Driedger A; Luster M; Kloos RT; Sherman S; Haugen B; Corone C; Molinaro E; Elisei R; Ceccarelli C; Pinchera A; Wahl RL; Leboulleux S; Ricard M; Yoo J; Busaidy NL; Delpassand E; Hanscheid H; Felbinger R; Lassmann M; Reiners C
J Clin Endocrinol Metab; 2006 Mar; 91(3):926-32. PubMed ID: 16384850
[TBL] [Abstract][Full Text] [Related]
9. Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma.
M'Kacher R; Legal JD; Schlumberger M; Voisin P; Aubert B; Gaillard N; Parmentier C
J Nucl Med; 1996 Nov; 37(11):1860-4. PubMed ID: 8917193
[TBL] [Abstract][Full Text] [Related]
10. Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma.
Pons F; Carrió I; Estorch M; Ginjaume M; Pons J; Milian R
Clin Nucl Med; 1987 Aug; 12(8):644-7. PubMed ID: 3117471
[TBL] [Abstract][Full Text] [Related]
11. 131I Biokinetics and cytogenetic dose estimates in ablation treatment of thyroid carcinoma.
Nascimento AC; Lipsztein JL; Corbo R; Rebelo AM
Health Phys; 2010 Oct; 99(4):457-63. PubMed ID: 20838086
[TBL] [Abstract][Full Text] [Related]
12. Radiation dose to the testes after 131I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer.
Ceccarelli C; Battisti P; Gasperi M; Fantuzzi E; Pacini F; Gualdrini G; Pierantoni MC; Luciani A; Djokich D; Pinchera A
J Nucl Med; 1999 Oct; 40(10):1716-21. PubMed ID: 10520714
[TBL] [Abstract][Full Text] [Related]
13. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
14. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study.
Ceccarelli C; Bencivelli W; Morciano D; Pinchera A; Pacini F
J Clin Endocrinol Metab; 2001 Aug; 86(8):3512-5. PubMed ID: 11502772
[TBL] [Abstract][Full Text] [Related]
15. Anaplastic changes associated with p53 gene mutation in differentiated thyroid carcinoma after insufficient radioactive iodine (131I) therapy.
Sera N; Ashizawa K; Ando T; Ide A; Abe Y; Usa T; Tominaga T; Ejima E; Hayashi T; Shimokawa I; Eguchi K
Thyroid; 2000 Nov; 10(11):975-9. PubMed ID: 11128725
[TBL] [Abstract][Full Text] [Related]
16. [The advantage of lithium in association with iodine 131 in the treatement of functioning metastasis of the thyroid cancer (author's transl)].
Brière J; Pousset G; Darsy P; Guinet
Ann Endocrinol (Paris); 1974; 35(3):281-2. PubMed ID: 4463794
[No Abstract] [Full Text] [Related]
17. Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements.
Liu B; Peng W; Huang R; Tian R; Zeng Y; Kuang A
Radiology; 2014 Oct; 273(1):211-9. PubMed ID: 24895877
[TBL] [Abstract][Full Text] [Related]
18. Sequential changes in serum thyroid peroxidase following radioiodine therapy of patients with differentiated thyroid carcinoma.
Ozata M; Bayhan H; Bingöl N; Dündar S; Beyhan Z; Corakci A; Gundogan MA
J Clin Endocrinol Metab; 1995 Dec; 80(12):3634-8. PubMed ID: 8530612
[TBL] [Abstract][Full Text] [Related]
19. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
[TBL] [Abstract][Full Text] [Related]
20. [The use of 131I in the combined modality therapy of highly differentiated cancer of the thyroid gland].
Baranauskas ZL; Mamontov VV; Valutskas KK
Med Radiol (Mosk); 1989 Oct; 34(10):31-4. PubMed ID: 2811625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
